APA (7th ed.) Citation

YK, V., D, N., A, D., S, S., C, K., R, O., . . . MB, G. (2024). Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax. Blood advances, 8(22), 5806. https://doi.org/10.1182/bloodadvances.2024013927

Chicago Style (17th ed.) Citation

YK, Valtis, Nemirovsky D, Derkach A, Sharan S, Kabel C, Ortiz R, Thompson MC, Roeker LE, and Geyer MB. "Real-world Incidence and Prevention of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Treated with Venetoclax." Blood Advances 8, no. 22 (2024): 5806. https://doi.org/10.1182/bloodadvances.2024013927.

MLA (9th ed.) Citation

YK, Valtis, et al. "Real-world Incidence and Prevention of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Treated with Venetoclax." Blood Advances, vol. 8, no. 22, 2024, p. 5806, https://doi.org/10.1182/bloodadvances.2024013927.